Check for Full TextE Allen, I Walters… - Clinical Cancer Research, 2011 - AACR ... evasive/adaptive resistance to VEGF inhibition ... 1 Brivanib, a dual FGF/VEGF inhibitor, is active both 1st and 2nd line against mouse pancreatic neuroendocrine tumors (PNET) developing adaptive/evasive resistance to VEGF inhibition ... Related articles - All 2 versions
Check for Full TextE Allen, IB Walters… - Clinical Cancer Research, 2011 - AACR Experimental Design: An anti-VEGFR2 monoclonal antibody (DC101), an inhibitor of FGF signaling (FGF ligand trap), sorafenib, and brivanib were comparatively evaluated in first-line monotherapy in short and longer term fixed endpoint intervention trials in the RIP-Tag2 mouse model of ... Cited by 2
Check for Full TextSH Millson, CS Chua, SM Roe, S Polier… - The FASEB Journal, 2011 - FASEB ABSTRACT Much attention is focused on the benzo- quinone ansamycins as anticancer agents, with several derivatives of the natural product geldanamycin (GdA) now in clinical trials. These drugs are selective inhibi- tors of Hsp90, a molecular chaperone vital for ...
[HTML] from nih.gov Check for Full TextR Rabøl, KF Petersen, S Dufour… - Proceedings of the …, 2011 - National Acad Sciences Skeletal muscle insulin resistance has been implicated in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and atherogenic dyslipidemia associated with the metabolic syndrome by altering the distribution pattern of postprandial energy storage. We conducted a study ...
[PDF] from nyu.edu Check for Full TextP Pandiyan, HR Conti, L Zheng, AC Peterson… - Immunity, 2011 - Elsevier Th17 cells and CD4 + CD25 + Foxp3 + regulatory T (Treg) cells are thought to promote and suppress inflammatory responses, respectively. Here we explore why under Th17 cell polarizing conditions, Treg cells did not suppress, but rather upregulated, the expression of ... Cited by 7 - Related articles - All 3 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
